Kalaris Therapeutics (KLRS)
NASDAQ:KLRS
Want to see KLRS full AI Analyst Report?
Top Page
Kalaris Therapeutics
(NASDAQ:KLRS)
Select Model
Select Model
Rating:46Neutral
Price Target:
$5.00
▼(-20.89% Downside)
Action:Reiterated
Date:05/15/26
The score is held down primarily by weak financial performance (pre-revenue, sizable ongoing losses and cash burn) and bearish technicals (below major moving averages with negative MACD). A positive offset is improved funding visibility/cash runway from recent corporate updates and financing, but profitability and self-funding capacity are not yet evident.
Positive Factors
Extended cash runway from $50M financing
The company strengthened its balance sheet via a $50M private placement and explicitly guided funding into Q4 2027. This durable funding visibility materially reduces near-term financing risk and supports advancing TH103 toward Phase 3, improving execution capacity over the next 2–3 years.
Negative Factors
Pre-revenue with sustained large losses
KLRS remains pre-revenue and incurred substantial net losses (~$43–44M in recent periods). Without product sales, profitability is structurally negative, meaning the company cannot self-fund operations and remains dependent on successful clinical outcomes and external capital over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Extended cash runway from $50M financing
The company strengthened its balance sheet via a $50M private placement and explicitly guided funding into Q4 2027. This durable funding visibility materially reduces near-term financing risk and supports advancing TH103 toward Phase 3, improving execution capacity over the next 2–3 years.
Read all positive factors
Kalaris Therapeutics (KLRS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$105.43M
Dividend YieldN/A
Average Volume (3M)136.22K
Price to Earnings (P/E)―
Beta (1Y)0.83
Revenue GrowthN/A
EPS Growth73.91%
CountryUS
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.15
Shares Outstanding23,792,278
10 Day Avg. Volume189,046
30 Day Avg. Volume136,224
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.63
Price to Sales (P/S)0.00
P/FCF Ratio-2.98
Enterprise Value/Market Cap0.54
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.87K
Enterprise Value/Ebitda-1.25
Forecast
1Y Price Target
$15.75Price Target Upside149.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.87
Revenue Forecast (FY)N/A
Kalaris Therapeutics Business Overview & Revenue Model
Company Description
Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severe...
How the Company Makes Money
As a clinical-stage biotechnology company, Kalaris Therapeutics has historically not depended on recurring product sales; its cash inflows are typically driven by financing activities rather than commercial revenue. Common sources include proceeds...
Kalaris Therapeutics Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
58
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -20.00K | -13.00K | 0.00 | 0.00 | 0.00 | -1.12M |
| EBITDA | -45.87M | -46.14M | -58.77M | -14.01M | -15.25M | -169.84M |
| Net Income | -44.10M | -43.44M | -58.77M | -14.70M | -15.48M | -171.96M |
Balance Sheet | ||||||
| Total Assets | 109.81M | 121.74M | 118.55M | 3.33M | 3.90M | 286.59M |
| Cash, Cash Equivalents and Short-Term Investments | 97.22M | 117.98M | 118.29M | 3.17M | 3.06M | 248.12M |
| Total Debt | 1.41M | 1.45M | 0.00 | 0.00 | 3.25M | 30.07M |
| Total Liabilities | 41.25M | 42.92M | 5.24M | 48.35M | 34.17M | 61.33M |
| Stockholders Equity | 68.56M | 78.81M | 113.31M | -45.02M | -30.27M | 225.27M |
Cash Flow | ||||||
| Free Cash Flow | -49.09M | -43.18M | -67.70M | -14.13M | -9.78M | -106.34M |
| Operating Cash Flow | -48.88M | -42.98M | -67.70M | -14.13M | -9.78M | -106.32M |
| Investing Cash Flow | -70.07M | -19.72M | 95.00M | 0.00 | 0.00 | 185.98M |
| Financing Cash Flow | 52.42M | 159.61M | 21.00K | 14.24M | 12.78M | 232.00K |
Kalaris Therapeutics Technical Analysis
Negative
6.32
Price Trends
6.10
Negative
7.75
Negative
6.49
Negative
Market Momentum
-0.43
Negative
37.05
Neutral
27.30
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KLRS, the sentiment is Negative. The current price of 6.32 is above the 20-day moving average (MA) of 5.26, above the 50-day MA of 6.10, and below the 200-day MA of 6.49, indicating a bearish trend. The MACD of -0.43 indicates Negative momentum. The RSI at 37.05 is Neutral, neither overbought nor oversold. The STOCH value of 27.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KLRS.
Kalaris Therapeutics Risk Analysis
Kalaris Therapeutics disclosed 75 risk factors in its most recent earnings report. Kalaris Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Kalaris Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $2.35B | -9.91 | -87.00% | ― | -36.24% | 11.52% | |
56 Neutral | $2.27B | -10.14 | -253.85% | ― | ― | -15.28% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $232.92M | -1.52 | -174.71% | ― | -76.26% | -9.93% | |
46 Neutral | $105.43M | -3.15 | -72.78% | ― | ― | 73.91% | |
46 Neutral | $267.60M | -4.47 | -80.61% | ― | 43.21% | -15.55% | |
43 Neutral | $74.18M | -1.07 | -127.30% | ― | ― | 49.74% |
* Healthcare Sector Average
KLRS
Kalaris Therapeutics
4.83
1.85
62.08%
CHRS
Coherus Biosciences
1.51
0.74
95.60%
NKTR
Nektar Therapeutics
69.49
60.00
632.48%
CLLS
Cellectis SA
3.66
2.14
140.79%
MCRB
Seres Therapeutics
7.66
-0.04
-0.52%
KOD
Kodiak Sciences
36.22
32.69
924.61%
Kalaris Therapeutics Corporate Events
Executive/Board Changes
Kalaris Therapeutics Announces CFO Resignation, Finance Leadership Shift
Neutral
Apr 10, 2026
On April 8, 2026, Kalaris Therapeutics, Inc. disclosed that Chief Financial Officer Matthew Gall had decided to resign from his position, with his departure to take effect on April 14, 2026. The move triggers a leadership transition in the finance...
Business Operations and StrategyPrivate Placements and Financing
Kalaris Updates TH103 Strategy and Highlights Cash Runway
Positive
Mar 9, 2026
On March 9, 2026, Kalaris Therapeutics released an updated corporate presentation for use at the Leerink Partners Global Healthcare Conference and other investor meetings, outlining revised timelines for data readouts from its Phase 1b/2 multi-asc...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.